Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23243896 | 0.91 | CTSA (0.40) | CTSAKCNH2CACNA1BMAOBGPR88 | |
| SCHEMBL21834297 | 0.84 | MAOB (0.39) | CTSAKCNH2CACNA1BMAOB | |
| SCHEMBL21834295 | 0.83 | CTSA (0.37) | CTSAKCNH2CACNA1BMAOB | |
| SCHEMBL23243863 | 0.81 | GPR88 (0.46) | KCNH2CACNA1BMAOBGPR88 | |
| SCHEMBL21834242 | 0.79 | MAOB (0.39) | CTSAKCNH2CACNA1BMAOB | |
| SCHEMBL21834233 | 0.77 | CTSA (0.37) | CTSAKCNH2CACNA1BMAOB | |
| SCHEMBL21834239 | 0.73 | MAOB (0.39) | KCNH2CACNA1BMAOB | |
| SCHEMBL29229816 | 0.73 | KDM4E (0.36) | CTSAKCNH2CACNA1BMAOB | |
| SCHEMBL21834330 | 0.72 | MAOB (0.40) | CTSAKCNH2CACNA1BMAOB | |
| SCHEMBL21834303 | 0.72 | MAOB (0.37) | KCNH2CACNA1BMAOBGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | claimed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | claimed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | claimed |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-03-14 | — | — | US | claimed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | claimed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | claimed |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | CTSA 3755/4885KCNH2 667/4885CACNA1B 108/4885 |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | CTSA 3755/4885KCNH2 667/4885CACNA1B 108/4885 |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | CTSA 3755/4885KCNH2 667/4885CACNA1B 108/4885 |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | CTSA 3755/4885KCNH2 667/4885CACNA1B 108/4885 |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | CTSA 3755/4885KCNH2 667/4885CACNA1B 108/4885 |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | CTSA 3755/4885KCNH2 667/4885CACNA1B 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.